Back to search
Warm Autoimmune Hemolytic Anemia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Warm Autoimmune Hemolytic Anemia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Warm Autoimmune Hemolytic Anemia trials you may qualify forThis study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb respon…
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines…
This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thr…
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cyto…
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glu…
This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous t…
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel…